{"organizations": [], "uuid": "dea05e75b81ee84e114bd8d094df5d29519a5f40", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-regeneron-reports-q4-adj-earnings/brief-regeneron-reports-q4-adj-earnings-per-share-5-23-idUSASB0C4PX", "country": "US", "domain_rank": 408, "title": "BRIEF-Regeneron Reports Q4 Adj. Earnings Per Share $5.23", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.992, "site_type": "news", "published": "2018-02-08T20:16:00.000+02:00", "replies_count": 0, "uuid": "dea05e75b81ee84e114bd8d094df5d29519a5f40"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-regeneron-reports-q4-adj-earnings/brief-regeneron-reports-q4-adj-earnings-per-share-5-23-idUSASB0C4PX", "ord_in_thread": 0, "title": "BRIEF-Regeneron Reports Q4 Adj. Earnings Per Share $5.23", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "regeneron pharmaceuticals inc", "sentiment": "negative"}, {"name": "regeneron pharma", "sentiment": "none"}, {"name": "sanofi", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "regeneron pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - Regeneron Pharmaceuticals Inc:\n* REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS\n* Q4 NON-GAAP EARNINGS PER SHARE $5.23 * Q4 GAAP EARNINGS PER SHARE $1.50 * REGENERON PHARMACEUTICALS - Q4 GAAP NET INCOME PER DILUTED SHARE INCLUDES CHARGE OF $2.82/DILUTED SHARE IN CONNECTION WITH U.S. TAX REFORM LEGISLATION\n* SEES, IN FY 2018, SANOFI COLLABORATION REVENUE OF $450 MILLION TO $500 MILLION\n* Q4 EYLEA (AFLIBERCEPT) INJECTION U.S. NET SALES INCREASED 14% TO $975 MILLION VERSUS Q4 2016\n* SEES FY 2018 CAPITAL EXPENDITURES OF $420 MILLION TO $500 MILLION\n* REGENERON PHARMA - TOTAL REVENUES, WHICH INCLUDE PRODUCT REVENUES , INCREASED BY 29% TO $1.582 BILLION IN Q4\n* Q4 EARNINGS PER SHARE VIEW $4.53, REVENUE VIEW $1.50 BILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T20:16:00.000+02:00", "crawled": "2018-02-08T14:28:31.014+02:00", "highlightTitle": ""}